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aid clinicians when advising patients and their caregivers
about prognosis and treatment.
PMH3
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OBJECTIVES: To assess the risk of diabetes among
patients undergoing treatment with risperidone vs.
haloperidol. A series of case reports had associated some
antipsychotic agents with diabetes.
METHODS: Patients with at least one prescription 
for either haloperidol or risperidone between January
1997 and 31st December 1999 recorded in the Regie de
l’Assurance Maladie de Quebec database, excluding 
those dispensed clozapine or olanzapine during the study
period or diagnosed with diabetes (deﬁned as either a
recorded ICD9 250.0 to 250.93 or a prescription for
insulin or an oral hypoglycemic agent) before beginning
anti-psychotic therapy, were divided into haloperidol
recipients (N = 14,602) and those receiving risperidone
but not haloperidol (N = 9,961). New diabetes diagnoses
after the ﬁrst antipsychotic prescription were tabulated;
censoring at study end or the last service date if there was
no record of using any services during the last six months
of follow-up. Crude hazard ratios and proportional
hazards analyses were carried out.
RESULTS: 406 patients developed diabetes after being
prescribed haloperidol, and 123 after risperidone, a crude
hazard ratio of 2.29 (95% CI 1.81–2.90). When correct-
ing for imbalances in age, and gender, using proportional
hazards analysis, haloperidol still increased the risk of
diabetes by 93% (HR = 1.93, 95% CI 1.57–2.37, 
P < 0.0001). Correction for other imbalances did not
change the ﬁndings.
CONCLUSIONS: Haloperidol was associated with an
increased risk of developing diabetes compared to risperi-
done. Additional studies are required to identify a bio-
logical basis for this association, and to examine other
atypical antipsychotics to determine which have the
lowest risk of diabetes.
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OBJECTIVE: To assess whether a 5-factor instead of 
3-factor model more completely describes the range of
psychotic symptoms as measured by the Positive and Neg-
ative Syndrome Scale (PANSS) with data from the Que-
tiapine Experience with Safety and Tolerability (QUEST)
trial, and to reevaluate the comparative efﬁcacy of queti-
apine and risperidone using the 5-symptom model.
METHODS: We used exploratory factor analysis (EFA)
to test whether three factors adequately describe symp-
toms as measured by the PANSS or if more factors are
needed. The initial EFA is carried out using only baseline
data. Evaluating the test for breaks in eigen values deter-
mines the number of factors. We used the n-factor rule to
retain and rotate enough factors to explain 99% of the
variation. Using the derived factorial structure, we per-
formed comparative analyses on the intent-to-treat (ITT)
population and on patients with clinically signiﬁcant
baseline symptoms (CSBS) at 2 and 4 months.
RESULTS: 554 patients had completed PANSS data; 
5 factors explained 99.9% of data variance and labeled
negative, positive, activation, dysphoria, and autistic pre-
occupation symptoms with corresponding eigen values
28.97, 7.55, 3.59, 2.63 and 1.45 explaining 66%, 17%,
8%, 6%, and 3% of the variation. Statistical analyses
found that, compared with risperidone, quetiapine con-
sistently improves dysphoria sooner and in patients with
CSBS. At 2 months quetiapine-treated patients’ absolute
change from baseline was -3.11 compared to -2.22 (P =
0.03). For patients with clinically signiﬁcant baseline 
negative symptoms, at 2-months the comparative change
in dsyphoria was -3.79 vs. -2.34 (P = 0.02). In patients
with clinically signiﬁcant positive symptoms, quetiapine
improved dsyphoria symptoms better than risperidone at
2 and 4-months, -4.06 vs. -2.24 (P = 0.01) and -4.73 vs.
-2.88 (P = 0.03).
CONCLUSIONS: PANSS is more completely described
with ﬁve symptoms. Compared with risperidone, queti-
apine displays clinical advantage in improving dysphoria
not evident when a 3-factor model is used.
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OBJECTIVES: Because clinical outcomes depression
treatment in primary care settings tend to be poor, we
developed and evaluated the efﬁcacy of two augmenta-
tions to antidepressant treatment to be delivered by
primary care nurses.
METHODS: We conducted a randomized trial compar-
ing usual care, telehealth care, and telehealth care plus
peer support for depressed patients seen in primary care
in an HMO setting. Assessments were conducted at base-
line, 6 weeks and 6 months after study enrollment at two
managed care adult primary care clinics. Participants
were 303 patients recently started on antidepressants. The
intervention consisted of: telehealth care; emotional
